Ibanga Lezemithi 1009119-65-6 I-Daclatasvir Yokwelapha I-Hepatitis C Isithombe Esifakiwe

I-Pharmaceutical Grade 1009119-65-6 I-Daclatasvir Yokwelapha I-Hepatitis C

Incazelo emfushane:

Ubumsulwa:≧99.0%

Amazinga Ekhwalithi:Njengoba kudingeka

Isitifiketi:I-COA, i-MOA, i-MSDS, njll.

Amandla:50Kgs ngenyanga

Impilo Yeshelufu:Iminyaka Emibili

Isicelo:i-inhibitor ye-nonstructural protein 5A futhi isetshenziselwa ukwelapha i-hepatitis C

Inzuzo Yeqembu:Ithimba labadayisi abanolwazi lokuthekelisa elinokuqeqeshwa kochwepheshe efektri

Thumela i-imeyili kithi Landa njenge-PDF

Imininingwane Yomkhiqizo

FAQ

Omaka bomkhiqizo

Umkhiqizoigama	I-Daclatasvir2HCl
Omqondofana	N,N'-[[1,1'-Biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1 -methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid dimethyl ester hydrochloride;I-BMS 790052
Inombolo ye-CAS.	1009119-65-6
Ukubukeka	Impushana emhlophe ukuya kokuphuzi
I-Molecular Formula	C₄₀H₅₀N₈O₆.2(HCl)
Isisindo samangqamuzana	811.81
Ukusetshenziswa	IBanga Lezemithi ngenjongo yocwaningo
Ukupakisha	Njengesicelo sakho
Isitoreji	Londoloza ezitsheni eziqinile, ezimelana nokukhanya endaweni epholile

I-Daclatasvir2HCl Cas:1009119-65-6
Izinto	Okujwayelekile	Imiphumela
Izici	Impushana emhlophe ukuya kokuphuzi	Impushana ephuzi
Okuqukethwe kwamanzi	≦1.0%	0.25%
Ubumsulwa	≧99%	99.7%
Ukungcola okukodwa	≦0.1%	0.06%
Izinsalela ekushiseni	≦0.1%	Iyahambisana
Isiphetho	Ihambisana nokucaciswa kwangaphakathi kwendlu.

Ulwazi Lwenkampani

√ Isipiliyoni esigcwele se-Management layer kubalandeli befektri nabanekhono;
√ Ikhwalithi ihlale iwukucatshangelwa kwethu okuphezulu, uhlelo oluqinile lwe-QC;
√ Ithimba leminyaka engu-11 elinesipiliyoni sokuthumela ngaphandle;
√ Ilebhu ye-R&D ezimele;
√ Izinkundla zokucobelelana ngolwazi ezimbili ze-GMP zesikhathi eside ezisayiniwe;
√ Izinsiza ezicebile zamafekthri amaningi angasebenzi wephrojekthi eyenziwe ngokwezifiso;
√ Ithimba elisebenzayo elisebenza kahle elinendlela engaguquki.
imgsaf